In a landmark development for India’s biotherapeutics landscape, Miltenyi Biotec India Private Limited and the Biotechnology Industry Research Assistance Council (BIRAC) signed a strategic Letter of Intent (LOI) at the BIO International Convention 2025 in Boston. This collaboration is set to accelerate India’s capabilities in Cell and Gene Therapy (CGT) through capacity building, translational research, and localized manufacturing.
The milestone event also marked the inauguration of the India Pavilion by Miltenyi Biotec India, alongside senior representatives from BIRAC and the Department of Biotechnology (DBT). The ceremonial ribbon-cutting highlighted India’s growing presence in global biotechnology innovation.
Capacity Building & Training: Structured programs to upskill clinicians, researchers, and technicians in CGT manufacturing, analytics, and quality control.
Translational Research: Co-development of academic and multi-center studies targeting therapies for malignancies, autoimmune disorders, and rare diseases.
Point-of-Care CAR-T Access: Establishing PoC CAR-T centers across India using Miltenyi’s CliniMACS Prodigy system for cost-effective and scalable treatments.
Local Innovation & Startups: Supporting Indian biotech startups with mentoring and fostering domestic manufacturing of critical CGT components in line with the Make in India mission.
Priya Kapoor-Hingorani, Managing Director, Miltenyi Biotec India, emphasized:
“Our partnership with BIRAC focuses on upskilling scientists and enhancing infrastructure to address unmet needs, particularly in autoimmune and rare diseases. Innovative solutions like point-of-care CAR-T and graft engineering will help improve access.”
Dr. Jitendra Kumar, Managing Director, BIRAC, added:
“India aspires to be a global leader in cell and gene therapy. This collaboration with Miltenyi brings world-class expertise to strengthen training and build skilled manpower.”
This partnership blends global technological expertise with public-sector commitment, aiming to create a sustainable infrastructure for next-generation therapeutics. It is expected to empower Indian innovators, benefit patients, and position India as a global hub in Cell and Gene Therapy.